Why ERAS? Erasca, Inc. Analysis, Price & AI Insights | Whystock
ERAS
$10.03-0.62 (-5.82%)
Market ClosedLast close May 1
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.